---
figid: PMC5812366__nihms934575f1
figtitle: Major mechanisms of therapeutic resistance to androgen axis-targeting therapies
  in prostate cancer
organisms:
- NA
pmcid: PMC5812366
filename: nihms934575f1.jpg
figlink: /pmc/articles/PMC5812366/figure/F1/
number: F1
caption: Major mechanisms of therapeutic resistance to androgen axis-targeting therapies
  in prostate cancer. A AR gene and mRNA amplifications to increase ligand sensitivity.
  B Utilization of nonandrogen ligands such as estradiol and glucocorticoids. C AR
  activation via alternative survival signaling pathways including PI3K/AKT, NF-κB,
  and RTKs. D AR coactivators can enhance AR sensitivity to various alternative ligands.
  E Utilization of alternative ligand synthesis pathways for conversion of adrenal
  androgen precursors. F Activation of TGF-β signaling pathway in EMT-to-MET interconversions.
  G Overexpression of prosurvival molecules such as Bcl-2 contributing to evasion
  of apoptosis activation. H AR splice variants with ligand-independent activation
  promote AR transcriptional programs in the absence of ligand
papertitle: Mechanisms of Therapeutic Resistance in Prostate Cancer.
reftext: Mary Nakazawa, et al. Curr Oncol Rep. ;19(2):13-13.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9323469
figid_alias: PMC5812366__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5812366__F1
ndex: da237d0c-df09-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5812366__nihms934575f1.html
  '@type': Dataset
  description: Major mechanisms of therapeutic resistance to androgen axis-targeting
    therapies in prostate cancer. A AR gene and mRNA amplifications to increase ligand
    sensitivity. B Utilization of nonandrogen ligands such as estradiol and glucocorticoids.
    C AR activation via alternative survival signaling pathways including PI3K/AKT,
    NF-κB, and RTKs. D AR coactivators can enhance AR sensitivity to various alternative
    ligands. E Utilization of alternative ligand synthesis pathways for conversion
    of adrenal androgen precursors. F Activation of TGF-β signaling pathway in EMT-to-MET
    interconversions. G Overexpression of prosurvival molecules such as Bcl-2 contributing
    to evasion of apoptosis activation. H AR splice variants with ligand-independent
    activation promote AR transcriptional programs in the absence of ligand
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CHST3
  - CYP17A1
  - SULT2A1
  - TGFB1
  - TGFB2
  - TGFB3
  - ITK
  - SLC22A3
  - IGF1
  - EGF
  - FGF7
  - TGFBR1
  - TGFBR2
  - AR
  - BAX
  - BAK1
  - SMAD2
  - SMAD3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - BCL2
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - SMAD4
  - MDM2
  - MTOR
  - NFKB1
  - NCOA4
  - FKBP4
  - FKBP5
  - TRIM24
  - Androgen
  - androgen
  - androgens
  - DHEA
  - estradiol
  - testosterone
  - Cancer
---
